Navigation Links
Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
Date:2/5/2013

PANAMA CITY, Feb. 5, 2013 /PRNewswire/ -- Novartis Pharma Logistics, Inc. announced today that it is voluntarily recalling certain lots of Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley's® Complete Liquids. Novartis Pharma Logistics has decided to issue a voluntary recall to consumers, retail customers and wholesalers in Curacao because the child-resistant feature of the bottle cap may not function properly, enabling the cap to be removed with the tamper-evident seal still in place. The affected bottle sizes are included at the end of this release.

Novartis Pharma Logistics has not received any adverse events due to the tamper evident seal causing a failure of the child resistant cap. Novartis Consumer Health, Inc. in the United States received four adverse events for Triaminic® Syrups related to this issue.

Triaminic® Syrups, Theraflu Warming Relief® Syrups, Jack & Jill® brand pediatric syrups and Buckley's® Complete Liquids continue to be safe and effective when used as directed on the package label.

The products being recalled were produced at a Novartis Consumer Health manufacturing facility in US prior to the voluntary suspension of operations in December 2011. In addition to production at the US manufacturing site, Buckley's Complete® was also produced until January 2013 at a third-party manufacturing site in Canada.  A consumer complaint in the US in late November 2012 triggered an internal investigation by Novartis Consumer Health that determined a voluntary recall was in the best interest of consumers.

Action to be taken by consumers
Novartis Pharma Logistics advises consumers who believe they have product included in this recall to discontinue use and return the recalled product to the s
'/>"/>

SOURCE Novartis Pharma Logistics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
3. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
4. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
5. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
6. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
7. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
8. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
9. FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
10. University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... LEIDEN, Netherlands, March 8, 2011 Johnson & Johnson (NYSE: ... CRXL ; Swiss Exchange: CRX) today announced that ... Subsequent Offering Period), Johnson & Johnson has acquired 98.89% ... treasury shares held by Crucell) and 98.93% of the issued ...
... 2011 Sequenom, Inc. (Nasdaq: SQNM ) today ... year ended December 31, 2010. (Logo:   http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ... Total revenue for the fourth quarter of 2010 grew 28% ... quarter of 2009. The increase in revenue compared to the ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 2Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 3Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 4Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 5Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 6Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 7Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 8Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results 9
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... ... Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. Collazo, ... Collazo, a 15 year veteran of helping drug, biologic and device firms reduce ...
(Date:7/30/2015)... ... 30, 2015 , ... World Patent Marketing, a vertically integrated ... that can help people during emergencies. , "The worldwide mobile health market revenue ... of World Patent Marketing. "Currently, there are about 97,000 mobile health apps available ...
(Date:7/30/2015)... ... ... In an effort to provide the twenty four hour continuous care desired by ... , The decision will also allow him to spend more time in the office ... admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always provided excellent ...
(Date:7/30/2015)... ... July 30, 2015 , ... In a meaningful ritual ... Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this with ... its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love with ...
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be disclosing ... discussed in a June 8, 2015 article published by Nasdaq , the powerful ... caused by its computer-driven cars, which such industry players as Tesla CEO Elon Musk ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3
... most common cancers in the world. Although the prognosis ... survival rate for those who receive operative treatment is ... surgical intervention. However, many surviving patients might suffer from ... in their later life. , A research article ...
... agent for treatment of patients with chronic hepatitis ... monotherapy leads to the emergence of lamivudine-resistant hepatitis ... infected with HBV. Sensitive methods for early detection ... decisions in treating patients with HBV infection. , ...
... no shortages here , , WEDNESDAY, Jan. 16 (HealthDay News) ... the safety gaps in the U.S. food system. , ... one federal "superagency" to monitor food safety; beefing up ... the very least, giving the FDA the ability to ...
... builds on success in Eastern Washington, SPOKANE, Wash., ... establishing a larger presence in the Spokane community.,The new ... are already employed by WDS in Spokane. Eventually, the ... tremendous success with our customer service center in,Colville and ...
... Dr. Judah,Folkman, founder of the field of angiogenesis, died ... one of the thousands of lectures,that he gave to ... Folkman was founder and director of the Vascular Biology,Program ... Surgery,and Cell Biology at Harvard Medical School., When ...
... Expected Recurring ... ... Rate ... Stereotaxis, Inc. (Nasdaq:,STXS) today reported that due to the previously delayed European launch of,its partnered ...
Cached Medicine News:Health News:What is the more suitable for early detection of low abundant lamivudine-resistant mutants? 2Health News:U.S. Food Safety: Solutions at a Glance 2Health News:U.S. Food Safety: Solutions at a Glance 3Health News:Washington Dental Service Opens Larger Spokane Office 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 3Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 4Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 2Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 3Health News:Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook 4
An Antiseptic - Antibacterial Cleanser that helps reduce bacteria that can potentially cause disease.Does not produce the systemic adverse effects associated with iodine or iodine by-products and is ...
... for professional degerming, pre-op and post-op ... combining quaternary and substituted phenolic active ... emollients and surfactants. Unprecedented efficacy on ... in 30 seconds. Techni-Care represents a ...
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... pouches are designed for individual application and ... used in nursing homes, home healthcare settings, ... other hospital departments. This unit dose pouch ... antiseptic, germicidal and cleansing agent. Hydrogen Peroxide's ...
Medicine Products: